The P2Y1 receptor as a target for new antithrombotic drugs: A review of the P2Y1 antagonist MRS-2179

Cardiovascular Drug Reviews

Volumn 21, Issue 1, 2003, Pages 67-76

  Baurand, Anthony ^a   Gachet, Christian ^a  

^a INSERM   (France)

Author keywords

Antithrombotics; MRS 2179; P2Y1 receptor antagonists; Platelet aggregation; Thrombosis

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 2 CHLORO N6 METHYLMETHANOCARBA 2' DEOXYADENOSINE 3',5' BISPHOSPHATE; 2' DEOXY 6 N METHYLADENOSINE 3',5' BISPHOSPHATE; 8 (2' DEOXY BETA DEXTRO RIBOFURANOSYL) 2 METHYL 4 (N METHYLAMINO)PYRAZOLO[1,5 A] 1,3,5 TRIAZINE 3',5' BISPHOSPHATE; ADENOSINE 3',5' BISPHOSPHATE; ANTICOAGULANT AGENT; AR C 69931MX; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; LOW MOLECULAR WEIGHT HEPARIN; MRS 2216; MRS 2279; N6 (2 METHYLTHIOETHYL) 2 (3,3,3 TRIFLUOROPROPYLTHIO) BETA DICHLOROMETHYLENE ATP; NCS 769; PURINE P2Y RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; PYRIDINE DERIVATIVE; THROMBIN INHIBITOR; TICLOPIDINE; UNCLASSIFIED DRUG;

ARTERY THROMBOSIS; CLINICAL TRIAL; DRUG ACTIVITY; DRUG RECEPTOR BINDING; DRUG TARGETING; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; THROMBOCYTE AGGREGATION; THROMBOEMBOLISM; VEIN THROMBOSIS;

EID: 0037255494     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2003.tb00106.x     Document Type: Review

References (52)

1. 1 receptor antagonist. Eur J Pharmacol 2001;412:213-221.
2. Bennett JS. Novel platelet inhibitors. Annu Rev Med 2001;52:161-184.
3. Bernat A, Vallee E, Maffrand JP, Gordon JL. The role of platelets and ADP in experimental thrombosis induced by venous stasis in the rat. Thromb Res 1988;52:65-70.
4. Boyer JL, Adams M, Ravi RG, Jacobson KA, Harden TK. 2-Chloro N(6)-methyl-(N)-methanocarba-2′-deoxyadenosine-3′,5′- bisphosphate is a selective high affinity P2Y(1) receptor antagonist. Br J Pharmacol 2002;135:2004-2010.
5. 6-methyl-2′-deoxyadenosine-3′,5′-bisphosphate. Br J Pharmacol 1998;124:1-3.
6. 1 receptor. Mol Pharmacol 1996;50:1323-1329.
7. 1 receptor: Pharmacological signaling and molecular properties. Drug Dev Res 1996;39:253-261.
8. Boyer JL, Zohn IE, Jacobson KA, Harden TK. Differential effects of P2-purinoceptor antagonists on phospholipase C- and adenylyl cyclase-coupled P2Y-purinoceptors. Br J Pharmacol 1994;113:614-620.
9. Brown S, King B, Kim Y, Jang S, Burnstock G, Jacobson K. Activity of novel adenine nucleotide derivatives as agonists and antagonists at recombinant rat P2X receptors. Drug Dev Res 2000;49:253-259.
10. Bultmann R, Starke K. P2-purinoceptor antagonists discriminate three contraction-mediating receptors for ATP in rat vas deferens. Naunyn Schmiedeberg's Arch Pharmacol 1994;349:74-80.
11. 1 receptors. J Med Chem 1998;41:183-190.
12. CAPRIE. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996;348:1329-1339.
13. 4 receptors: Characterization of a suramin and PPADS-insensitive response to UTP. Br J Pharmacol 1996;119:1301-1303.
14. Chattaraj SC. Cangrelor AstraZeneca. Curr Opin Invest Drugs 2001;2:250-255.
15. Denis C, Methia N, Frenette PS, et al. A mouse model of severe von Willebrand disease: Defects in hemostasis and thrombosis. Proc Natl Acad Sci USA 1998;95:9524-9529.
16. 1-deficient mice. Nat Med 1999;5:1199-1202.
17. 1-receptors in human platelets which are pharmacologically distinct from P2Y(ADP)-receptors. Br J Pharmacol 1998;124:157-164.
18. Foster CJ, Prosser DM, Agans JM, et al. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest 2001;107:1591-1598.
19. Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost 2001;86:222-232.
20. Harden TK, Boyer JL, Nicholas RA. P2-purinergic receptors: Subtype-associated signaling responses and structure. Annu Rev Pharmacol Toxicol 1995;35:541-579.
21. Harker LA, Slichter SJ. The bleeding time as a screening test for evaluation of platelet function. N Engl J Med 1972;287:155-159.
22. 1 receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel. Br J Haematol 1998;103:858-866.
23. 1 receptor is necessary for adenosine 5′-diphosphate-induced platelet aggregation. Blood 1998;92:152-159.
24. 1 receptor induces platelet hyperreactivity in transgenic mice. J Thromb Haemost 2002;1:155-163.
25. Herault JP, Dol F, Gaich C, Bernat A, Herbert JM. Effect of clopidogrel on thrombin generation in plateletrich plasma in the rat. Thromb Haemost 1999;81:957-960.
26. Herault JP, Peyrou V, Savi P, Bernat A, Herbert JM. Effect of SR121566A, a potent GP IIb-Illa antagonist on platelet-mediated thrombin generation in vitro and in vivo. Thromb Haemost 1998;79:383-388.
27. Herbert JM, Bernat A, Maffrand JP. Importance of platelets in experimental venous thrombosis in the rat. Blood 1992;80:2281-2286.
28. Hollopeter G, Jantzen HM, Vincent D, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001;409:202-207.
29. Hourani SMO. Pharmacology of the platelet ADP receptors: Agonists and antagonists. Haematologica 2000;85:58-65.
30. Humphries RG. Pharmacology of AR-C69931MX and related compounds: from pharmacological tools to clinical trials. Haematologica 2000;85:66-72.
31. Humphries RG, Tomlinson W, Ingall AH, Cage PA, Leff P. FPL 66096: A novel, highly potent and selective antagonist at human platelet P2T-purinoceptors. Br J Pharmacol 1994;113:1057-1063.
32. Ingall AH, Dixon J, Bailey A, et al. Antagonists of the platelet P2T receptor: A novel approach to antithrombotic therapy. J Med Chem 1999;42:213-220.
33. Jacobson KA, Xu B, Cattaneo M, et al. Interaction of ribose-modified nucleotides with P2Y receptors in platelets. Haematologica 2002;87(Suppl):3-4.
34. Jin J, Kunapuli SP. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc Natl Nall Acad Sci USA 1998;95:8070-8074.
35. 1 receptor: Structure-activity relationships and receptor docking. J Med Chem 2001;44:3092-3108.
36. Kim YC, Gallo-Rodriguez C, Jang SY, et al. Acyclic analogues of deoxyadenosine 3′,5′-bisphosphates as P2Y(1) receptor antagonists. J Med Chem 2000;43:746-755.
37. Lambrecht G, Friebe T, Grimm U, et al. PPADS, a novel functionally selective antagonist of P2 purinoceptor-mediated responses. Eur J Pharmacol 1992;217:217-219.
38. 1 receptor deficient mice. Thromb Haemost 2001;abstract cited in the CDROM of abstracts of the VIIIth Congress of the ISTH.
39. 1 receptor antagonist. J Thromb Haemost 2003;in press.
40. 1 antagonist. Circulation 2001;103:718-723.
41. 1 receptor-null mice. J Clin Invest 1999;104:1731-1737.
42. 12 receptors in platelet-mediated aspects of coagulation. Haematologica 2002;87(Suppl):20-21.
43. 1 receptor antagonists and partial agonists. J Med Chem 1999;42:1625-1638.
44. 1 receptor ligands. J Med Chem 2000;43:829-842.
45. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation 1999;100:1667-1672.
46. 1 purinergic receptor: Synthesis and conformational analysis using potentiometric and nuclear magnetic resonance titration techniques. J Med Chem 2002;45:962-972.
47. 1 receptor antagonists. J Org Chem 2002;67:8063-8071.
48. Sabatine MS, Jang IK. The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease. Am J Med 2000;109:224-237.
49. 12, a new platelet ADP receptor, target of clopidogrel. Biochem Biophys Res Commun 2001;283:379-383.
50. Storey RF, Oldroyd KG, Wilcox RG. Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb Haemost 2001;85:401-407.
51. Tomlinson W, Cusworth E, Midha A, Kirk IP, Humphries RG, Leff P. Characterization of the P2T receptor antagonist properties of AR-C69931MX in human washed platelets in vitro. Haematologica 2000;85(Suppl):95-96.
52. Ziganshin AU, Hoyle CH, Bo X, et al. PPADS selectively antagonizes P2X-purinoceptor-mediated responses in the rabbit urinary bladder. Br J Pharmacol 1993;110:1491-1495.